Trial Profile
A Phase IIb trial of Exendin 9-39 for Post-Bariatric Hypoglycemia (PBH)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Avexitide (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- 06 Dec 2016 New trial record
- 29 Nov 2016 According to an Eiger BioPharmaceuticals media release, completed trial data (see profile 266884) will trigger initiation of this trial planned in 2017.